Holding(s) in Company

RNS Number : 8244T
Haleon PLC
26 July 2022
 

26 July 2022

 

Haleon plc

TR-1: S tandard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)


1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Haleon plc

1b. Please indicate if the issuer is a non-UK issuer   (please mark with an "X" if appropriate)

Non-UK issuer


2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments


An event changing the breakdown of voting rights


Other (please specify):


3. Details of person subject to the notification obligation

Name

GSK plc

City and country of registered office (if applicable)

London, England

4. Full name of shareholder(s) (if different from 3.)

Name

Vidacos Nominees Limited

City and country of registered office (if applicable)

London, England

5. Date on which the threshold was crossed or reached :

25 July 2022

6. Date on which issuer notified (DD/MM/YYYY):

25/07/2022

7. Total positions of person(s) subject to the notification obligation


% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B)

Resulting situation on the date on which threshold was crossed or reached

12.94

0

12.94

1,195,320,110

Position of previous notification (if applicable)

12.94

0

12.94


 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

A: Voting rights attached to shares

Class/type of
shares

ISIN code (if possible)

Number of voting rights

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BMX86B70

0

1,195,320,110

0

12.94











SUBTOTAL 8. A

1,195,320,110

12.94

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expiration
date

Exercise/
Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/converted.

% of voting rights


















SUBTOTAL 8. B 1



 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expiration
date

Exercise/
Conversion Period

Physical or cash Settlement

Number of voting rights

% of voting rights





















 

SUBTOTAL 8.B.2



 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii


Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)

X

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

GSK plc (Chain 1)

5.44


5.44

GlaxoSmithKline Holdings Limited (Chain 1)

5.44


5.44

GlaxoSmithKline Finance plc (Chain 1)

5.44


5.44

Glaxo Group Limited (Chain 1)

5.44


5.44





GSK plc (Chain 2)

4.74


4.74

GSK LP Limited (Chain 2)

4.74


4.74

GSK GP 1 Limited (Chain 2)

4.74


4.74

GSK (No. 1) Scottish Limited Partnership (Chain 2)

4.74


4.74





GSK plc (Chain 3)

1.78


1.78

GSK LP Limited (Chain 3)

1.78


1.78

GSK GP 1 Limited (Chain 3)

1.78


1.78

GSK (No. 2) Scottish Limited Partnership (Chain 3)

1.78


1.78





GSK plc (Chain 4)

0.98


0.98

GSK LP Limited (Chain 4)

0.98


0.98

GSK GP 2 Limited (Chain 4)

0.98


0.98

GSK (No. 3) Scottish Limited Partnership (Chain 4)

0.98


0.98

 

10. In case of proxy voting, please identify:

Name of the proxy holder


The number and % of voting rights held


The date until which the voting rights will be held



11. Additional information

This notification relates to the transfer by GSK plc of its direct retained 5.44% stake in Haleon plc to Glaxo Group Limited (a wholly owned subsidiary of GSK plc and the holder of other external minority

interests of the GSK group).

 

The GSK group's aggregate interest in Haleon plc remains unchanged following the transfer.  A separate TR-1 has also been submitted today by GSK plc on behalf of Glaxo Group Limited and Glaxo Group Limited's parent undertakings (other than GSK plc) to satisfy their notification obligations.

 

Glaxo Group Limited, GSK (No. 1) Scottish Limited Partnership, GSK (No. 2) Scottish Limited Partnership and GSK (No. 3) Scottish Limited Partnership hold their shares in Haleon plc via a custodian, Vidacos Nominees Limited, which holds the legal title to those shares on their behalf pursuant to a custody

arrangement.

 

These calculations are based on an issued share capital of Haleon plc of 9,234,573,831 ordinary shares.

 

 

Place of completion

London, England

Date of completion

25 July 2022

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUNUNRUAUBUAR

Companies

Haleon (HLN)
UK 100

Latest directors dealings